Effectiveness and Safety of Lenvatinib and Everolimus after Immune Checkpoint Inhibitors in Metastatic Renal Cell Cancer: A Systematic Review
Real-world evidence suggests that lenvatinib and everolimus represent an effective and safe option after ICI failure in mRCC patients. Nevertheless, the lack of randomized phase III trials and the heterogeneity of existing studies highlight the need for more robust prospective research to guide post-ICI therapeutic strategies.
Authors
- Sebastiano Buti (ORCID: https://orcid.org/0000-0003-0876-0226)
- Matteo Santoni (ORCID: https://orcid.org/0000-0001-7340-6173)
- Michele Maffezzoli (ORCID: https://orcid.org/0000-0001-7877-8988)
- Luca Traman
- Gelsomina Iovane (ORCID: https://orcid.org/0000-0003-3078-6692)
- Domenico Corradi
- Debora Guareschi
- Giuseppe Fornarini
Institutions
- University of Parma (IT)
Publication Details
- Journal
- Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics
- Published
- 2025-11-25
- DOI
- https://doi.org/10.32604/or.2025.070523
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00